US MEDICAL INNOVATIONS

Jerome Canady Research Institute for Advanced Biological and Technological Sciences Discovers Regulatory Gene BCL2A1 for Treatment of Triple-Negative Breast Cancer

Retrieved on: 
Tuesday, March 15, 2022
Oncology, Health, Medical Devices, Genetics, Research, Science, Biotechnology, Breast cancer, TNBC, MD, Prognosis, Academy of Technological Sciences of Ukraine, Plasma, Sirna, LLC, BCL2A1, Growth hacking, CHCP, Scientific Reports, Woman, Cancer, CELL, Triple-negative breast cancer, Cell death, Pharmaceutical industry, Vaccine, Medical imaging, JCRI-ABTS, US Medical Innovations, JCRI-ABTS, US MEDICAL INNOVATIONS

The Jerome Canady Research Institute for Advanced Biological and Technological Sciences (JCRI-ABTS), announced today that their recent article, BCL2A1 REGULATES CANADY HELIOS COLD PLASMA-INDUCED CELL DEATH IN TRIPLE-NEGATIVE BREAST CANCER (TNBC) , has been published in Scientific Reports, a Nature Portfolio journal.

Key Points: 
  • The Jerome Canady Research Institute for Advanced Biological and Technological Sciences (JCRI-ABTS), announced today that their recent article, BCL2A1 REGULATES CANADY HELIOS COLD PLASMA-INDUCED CELL DEATH IN TRIPLE-NEGATIVE BREAST CANCER (TNBC) , has been published in Scientific Reports, a Nature Portfolio journal.
  • JCRI-ABTSs scientists demonstrated that a combination of Canady Helios Cold Plasma (CHCP) and anti-BCL2A1 treatment may be beneficial and a novel therapeutic option for triple-negative breast cancer and other solid tumor cancers.
  • BCL2A1 expression plays an important role in cell survival after CHCP treatment in breast cancer cells and is potentially regulated by TNF-alpha.
  • Silencing BCL2A1 by siRNA treatment or by downregulating its expression by CPI203 treatment in combination with CHCP significantly increases the potency of the CHCP treatment.

JCRI Discovers the Mechanism using Canady Helios™ Cold Plasma to Induce Cell Death in Breast Cancer

Retrieved on: 
Thursday, September 2, 2021
Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, LLC, Apoptosis, IDE, Plasma, News, CHCP, Canadian International Council, Breast cancer, Conference, Sheba Medical Center, Cancer, Redox, Cell death, FDA, Woman, Research, Cell cycle, La Trobe Institute for Molecular Science, CEO, Academy of Technological Sciences of Ukraine, Rush University Medical Center, Clinical trial, Cell proliferation, International Journal of Molecular Sciences, Pharmaceutical industry, Medical imaging, JCRI-ABTS, US Medical Innovations, JCRI-ABTS, US MEDICAL INNOVATIONS

The Jerome Canady Research Institute for Advanced Biological and Technological Sciences (JCRI-ABTS), in collaboration with US Medical Innovations, LLC (USMI) , announced today that they have discovered the mechanism using Canady Helios Cold Plasma (CHCP) to induce cell death in breast cancer.

Key Points: 
  • The Jerome Canady Research Institute for Advanced Biological and Technological Sciences (JCRI-ABTS), in collaboration with US Medical Innovations, LLC (USMI) , announced today that they have discovered the mechanism using Canady Helios Cold Plasma (CHCP) to induce cell death in breast cancer.
  • Recently accepted for publication in the International Journal of Molecular Sciences, the article Canady Helios Cold Plasma Induces Breast Cancer Cell Death by Oxidation of Histone mRNA described how research scientists at JCRI/ABTS treated four (4) breast cancer cell lines with Canady Helios Cold Plasma (CHCP) at different dosages and monitored the progress of apoptosis (cell death).
  • Inhibition of cell proliferation, induction of apoptosis, and disruption of cell cycle were all observed during the early S-phase of the cell cycle.
  • JCRI-ABTS is a state-of-the-art BSL 2 translational molecular research laboratory focusing on Plasma Oncotherapeutics (a new cancer treatment modality) using Canady Helios Cold Plasma to investigate the potential of Cold Atmospheric Plasma to selectively treat cancer.

JCRI-ABTS and USMI Successfully Use Canady Helios™ Cold Plasma in Combination with FOLFIRINOX for the Treatment of Cholangiocarcinoma

Retrieved on: 
Wednesday, April 28, 2021
Research, Medical devices, FDA, Clinical trials, Other Health, Biotechnology, General Health, Health, Science, Oncology, Cancer treatments, Cancer, Clinical medicine, Chemotherapy regimens, FOLFIRINOX, FOLFIRI, Chemotherapy, 7+3, JCRI-ABTS, US Medical Innovations, JCRI-ABTS, US MEDICAL INNOVATIONS

Current treatments include systemic chemotherapeutic regimens such as FOLFIRINOX.

Key Points: 
  • Current treatments include systemic chemotherapeutic regimens such as FOLFIRINOX.
  • A limitation of this chemotherapy regimen is its toxicity and adverse events.
  • There exists a need for therapies to alleviate the toxicity of a FOLFIRINOX regimen while enhancing, or not altering, its anticancer properties.\nAccording to Jerome Canady, MD, and Chief Science Officer, \xe2\x80\x9cOur analysis of cell viability, proliferation, and the cell cycle demonstrated that CHCAP in combination with FOLFIRINOX is more effective than either treatment alone.
  • USMI is dedicated to expanding the boundaries of plasma medicine by pioneering new technologies for the development of state-of-the-art medical devices that advance patient outcomes and improve human lives.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210428005762/en/\n'

JCRI-ABTS and USMI Successfully Complete Phase 1 Multi-Center Clinical Trial Using Canady Helios™ Cold Plasma for the Treatment of Cancer

Retrieved on: 
Tuesday, April 20, 2021
Science, Biotechnology, Research, Surgery, Oncology, Health, Medical devices, Clinical trials, Spacecraft, Spaceflight, Medical physics, Radiobiology, Canady, Radiation therapy, Helios, Physical sciences, JCRI-ABTS, US Medical Innovations, JCRI-ABTS, US MEDICAL INNOVATIONS

b'The Jerome Canady Research Institute for Advanced Biological and Technological Sciences, LLC (JCRI-ABTS) and US Medical Innovations, LLC (USMI) announced today that they have successfully completed Phase 1 in their Clinical Trial using Canady Helios\xe2\x84\xa2 Cold Plasma (CHCP) for the treatment of recurrent and stage 4 solid tumors (IDE #G190195).

Key Points: 
  • b'The Jerome Canady Research Institute for Advanced Biological and Technological Sciences, LLC (JCRI-ABTS) and US Medical Innovations, LLC (USMI) announced today that they have successfully completed Phase 1 in their Clinical Trial using Canady Helios\xe2\x84\xa2 Cold Plasma (CHCP) for the treatment of recurrent and stage 4 solid tumors (IDE #G190195).
  • This novel non-thermal process (24-27o C) has been developed for treating solid cancerous tumors.
  • Canady continued, \xe2\x80\x9cUnlike Chemo and Radiation Therapy, the Canady Helios\xe2\x84\xa2 Cold Plasma Therapy has many advantages.
  • It is highly selective because it only targets cancer cells without damaging surrounding healthy tissue.